Pharvaris/$PHVS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pharvaris

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Ticker

$PHVS
Primary listing

Industry

Pharmaceuticals

Headquarters

Zug, Switzerland

Employees

119

ISIN

NL00150005Y4

Pharvaris Metrics

BasicAdvanced
$1B
-
-$3.30
-2.86
-

What the Analysts think about Pharvaris

Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.

Bulls say / Bears say

Pharvaris's lead drug candidate, deucrictibant, has received orphan designation from the European Commission, highlighting its potential as a novel oral treatment for hereditary angioedema (HAE). (Pharvaris News Releases)
Analysts at JMP Securities have maintained a 'Market Outperform' rating with a $55 price target, citing the company's strong financial position and upcoming Phase 3 data for deucrictibant. (Investing.com)
Pharvaris has initiated enrollment in its Phase 3 RAPIDe-3 trial for the on-demand treatment of HAE attacks, demonstrating effective execution of its clinical strategy. (Investing.com)
Pharvaris reported a net loss of $30 million in Q1 2024, with operating expenses exceeding expectations due to elevated R&D costs. (Investing.com)
The company's stock has experienced volatility, trading between $11.83 and $25.01 over the past year, reflecting typical fluctuations in biotech firms during developmental phases. (DirectorsTalk Interviews)
Pharvaris's financials show a negative free cash flow of -$79.65 million, underscoring the capital-intensive nature of its ongoing clinical trials. (DirectorsTalk Interviews)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Pharvaris Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Pharvaris Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PHVS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs